AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8535321 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMT
Number of subjects: 0
Study 8535321 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 0
Study 2311219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation during repletion
Number of subjects: 11
Study 2311219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6138551 — intervention group
Group type: EXPERIMENTAL
Intervention: Lambswool bedding
Number of subjects: 34
Study 6138551 — intervention group
Group type: COMPARATOR
Intervention: Cotton sheets (control)
Number of subjects: 34
Study 31308304 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily insulin degludec/insulin aspart (IDegAsp), n = 26
Number of subjects: 52
Study 31308304 — intervention group
Group type: COMPARATOR
Intervention: Once-daily basal insulin (insulin degludec and insulin glargine 300 units/mL), n = 26
Number of subjects: 52
Study 27801991 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (b-MI)
Number of subjects: 316
Study 27801991 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 316
Study 25679398 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoietin‐α treatment
Number of subjects: 36
Study 25679398 — intervention group
Group type: EXPERIMENTAL
Intervention: Training-ESA group
Number of subjects: 36
Study 25679398 — intervention group
Group type: COMPARATOR
Intervention: Sedentary-placebo
Number of subjects: 36
Study 25679398 — intervention group
Group type: COMPARATOR
Intervention: Sedentary-ESA
Number of subjects: 36
Study 25679398 — intervention group
Group type: COMPARATOR
Intervention: Training-placebo
Number of subjects: 36
Study 23594239 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dose of 325 mg of aspirin (ASA)
Number of subjects: 24
Study 23594239 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 24
Study 21394642 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (B(2) agonist)
Number of subjects: 11
Study 21394642 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 11
Study 21394642 — intervention group
Group type: COMPARATOR
Intervention: Lys‐des‐Arg(9)‐bradykinin (B(1) agonist)
Number of subjects: 11
Study 21394642 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin with angiotensin‐converting enzyme inhibition
Number of subjects: 11
Study 19714604 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab (1, 4, or 10 mg/kg)
Number of subjects: 449
Study 19714604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 19714604 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 449
Study 20519906 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B hemoperfusion
Number of subjects: 64
Study 20519906 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 64
Study 16298691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiabetic patients with a history of severe chest pain attacks
Number of subjects: 568
Study 16298691 — intervention group
Group type: COMPARATOR
Intervention: Diabetic patients
Number of subjects: 568
Study 12040135 — intervention group
Group type: EXPERIMENTAL
Intervention: Early interventive social service program
Number of subjects: 105
Study 9784084 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day for 6 days
Number of subjects: 10
Study 9784084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7929869 — intervention group
Group type: EXPERIMENTAL
Intervention: CL 275,838 (50 mg)
Number of subjects: 16
Study 7929869 — intervention group
Group type: EXPERIMENTAL
Intervention: CL 275,838 (100 mg)
Number of subjects: 16
Study 7929869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3361785 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 14
Study 3361785 — intervention group
Group type: COMPARATOR
Intervention: Normal (N2O/O2) anesthesia
Number of subjects: 14
Study 30591703 — intervention group
Group type: EXPERIMENTAL
Intervention: C₁‐L protocol group (n=293)
Number of subjects: 408
Study 30591703 — intervention group
Group type: COMPARATOR
Intervention: OC‐L protocol group (n=91)
Number of subjects: 408
Study 30591703 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist protocol group (n=80)
Number of subjects: 408
Study 30591703 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 408
Study 27152422 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of IV dexamethasone before general anesthesia, BIS 35-45
Number of subjects: 140
Study 27152422 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of IV dexamethasone before general anesthesia, BIS 46-55
Number of subjects: 140
Study 27152422 — intervention group
Group type: COMPARATOR
Intervention: No dexamethasone, BIS 35-45
Number of subjects: 140
Study 27152422 — intervention group
Group type: COMPARATOR
Intervention: No dexamethasone, BIS 46-55
Number of subjects: 140
Study 24717957 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyzed acid water (EAW) nasal irrigation daily for 2 months
Number of subjects: 185
Study 24717957 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral normal saline (NS) nasal irrigation daily for 2 months
Number of subjects: 185
Study 24717957 — intervention group
Group type: COMPARATOR
Intervention: No nasal irrigation after surgery
Number of subjects: 185
Study 21996342 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose allergen patches
Number of subjects: 132
Study 21996342 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 132
Study 20469958 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic counseling program utilizing a predictive model
Number of subjects: 43497
Study 20469958 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 43497
Study 18310048 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular cells from pregnant patients
Number of subjects: 40
Study 15892409 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of i.v. lidocaine and nitrous oxide in oxygen inhalation
Number of subjects: 102
Study 15892409 — intervention group
Group type: COMPARATOR
Intervention: i.v. lidocaine
Number of subjects: 102
Study 15892409 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide in oxygen inhalation
Number of subjects: 102
Study 12883063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention leaflet containing additional information on risks and uncertainties
Number of subjects: 300
Study 12883063 — intervention group
Group type: COMPARATOR
Intervention: Control group based on an NHS Cervical Screening Programme leaflet
Number of subjects: 300
Study 10565453 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary bile alcohols in infants with mild to severe cholestasis
Number of subjects: 6
Study 10565453 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary bile alcohols in infants with slight cholestasis
Number of subjects: 6
Study 10565453 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of urinary bile alcohol spectrum in infants vs adults
Number of subjects: 6
Study 10565453 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of bile alcohols carrying chenodeoxycholic acid type nucleus
Number of subjects: 6
Study 10565453 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of 5beta-cholestane-3alpha,7alpha,24,25-tetrol
Number of subjects: 6
Study 8941648 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS type III CPS‐tetanus toxoid conjugate (III‐TT) vaccine (highest dose)
Number of subjects: 100
Study 8941648 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconjugated GBS type III CPS
Number of subjects: 100
Study 8941648 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 100
Study 2021794 — intervention group
Group type: EXPERIMENTAL
Intervention: Novo radioisotope based dual photon densitometer
Number of subjects: 94
Study 2021794 — intervention group
Group type: COMPARATOR
Intervention: Lunar X-ray densitometer
Number of subjects: 94
Study 6313595 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir 200 mg every 6 hours from day 8 to day 35 after transplantation
Number of subjects: 39
Study 6313595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 6313595 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 39
Study 31022980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training intervention group
Number of subjects: 0
Study 31022980 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioural control group
Number of subjects: 0
Study 29308944 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test or colonoscopy (specific intervention details not provided)
Number of subjects: 0
Study 29308944 — intervention group
Group type: COMPARATOR
Intervention: N/A (non-participants)
Number of subjects: 0
Study 29308944 — intervention group
Group type: EXPERIMENTAL
Intervention: N/A (participants)
Number of subjects: 0
Study 29308944 — intervention group
Group type: EXPERIMENTAL
Intervention: N/A (both groups)
Number of subjects: 0
Study 27333284 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 2.5, 5, or 7.5 mg b.i.d. for 4 months
Number of subjects: 8555
Study 25181937 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group exercise program
Number of subjects: 203
Study 22606977 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention (biweekly visits for 2 months, then weekly)
Number of subjects: 228
Study 22606977 — intervention group
Group type: COMPARATOR
Intervention: Standard care (adherence counselling, monthly health check, drug refills)
Number of subjects: 228
Study 22606977 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 228
Study 22606977 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 228
Study 20958200 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-administered questionnaire (Web SAQ)
Number of subjects: 190
Study 20958200 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil self-administered questionnaire
Number of subjects: 190
Study 17066232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial adjuvant chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5FU)
Number of subjects: 22
Study 17066232 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 22
Study 17066232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial adjuvant chemotherapy
Number of subjects: 22
Study 15750369 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (flexion‐distraction chiropractic manipulation and trigger point therapy)
Number of subjects: 111
Study 15750369 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (sham manipulation and effleurage)
Number of subjects: 111
Study 11493843 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe lifting arm (intensive training in back care, patient assessment, and handling techniques with improved patient handling techniques using manual equipment)
Number of subjects: 0
Study 11493843 — intervention group
Group type: EXPERIMENTAL
Intervention: No strenuous lifting arm (intensive training in back care, patient assessment, and handling techniques with additional mechanical and other assistive equipment)
Number of subjects: 0
Study 11493843 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned)
Number of subjects: 0
Study 9716141 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygosity for the factor V (Arg506-->Gln) mutation
Number of subjects: 108
Study 9716141 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers of the factor V (Arg506-->Gln) mutation
Number of subjects: 108
Study 9716141 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postoperative APC ratios
Number of subjects: 108
Study 9716141 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postoperative prothrombin fragment 1+2, thrombin-antithrombin complexes and soluble fibrin levels
Number of subjects: 108
Study 7981088 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 237
Study 2541975 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10
Study 2541975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 4097650 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preparation of triiodothyronine and thyroxine (1:4 ratio)
Number of subjects: 87
Study 4097650 — intervention group
Group type: COMPARATOR
Intervention: Thyroxine alone
Number of subjects: 87
Study 31746623 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized interview (WHO/PAHO) for diagnosing night blindness (NB)
Number of subjects: 0
Study 31746623 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroretinography for diagnosing night blindness (NB)
Number of subjects: 0
Study 31746623 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentrations of retinol
Number of subjects: 0
Study 30861580 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (120 mg and 240 mg)
Number of subjects: 2850
Study 30861580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2850
Study 28113032 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg once per day for 5 years)
Number of subjects: 4136
Study 28113032 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (1 mg once per day for 5 years)
Number of subjects: 4136
Study 28113032 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 4136
Study 25641570 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (HBIg) + lamivudine (LAM) followed by long-term prophylaxis with LAM
Number of subjects: 29
Study 25641570 — intervention group
Group type: COMPARATOR
Intervention: Long-term prophylaxis with LAM without HBIg
Number of subjects: 29
Study 25641570 — intervention group
Group type: EXPERIMENTAL
Intervention: Both prophylactic strategies (HBIg + LAM and LAM alone)
Number of subjects: 29
Study 25641570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-deep pyrosequencing (UDPS) analysis
Number of subjects: 29
Study 23279614 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily extended-release tacrolimus (LCPT)
Number of subjects: 326
Study 23279614 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus twice daily (control)
Number of subjects: 326
Study 21063726 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity vibration (HLV, f = 300 Hz)
Number of subjects: 18
Study 21063726 — intervention group
Group type: COMPARATOR
Intervention: Resistance training program (cR group, n = 18)
Number of subjects: 18
Study 19930092 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored oral health educational programme
Number of subjects: 113
Study 19930092 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 113
Study 17250932 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine (approximately 50,000 PFU)
Number of subjects: 21
Study 17250932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15489368 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma light (2 seconds)
Number of subjects: 9
Study 15489368 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity quartz halogen light (10 seconds)
Number of subjects: 9
Study 15489368 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard quartz halogen light (20 seconds)
Number of subjects: 9
Study 15489368 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma light (4 seconds)
Number of subjects: 9
Study 10665552 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (80 mg orally twice daily)
Number of subjects: 9233
Study 10665552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sibrafiban (3.0 mg, 4.5 mg, or 6.0 mg)
Number of subjects: 9233
Study 10665552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sibrafiban (3.0 mg, 4.5 mg, or 6.0 mg)
Number of subjects: 9233
Study 10665552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sibrafiban
Number of subjects: 9233
Study 10665552 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 9233
Study 10665552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sibrafiban
Number of subjects: 9233
Study 9374092 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 as a 1-hour infusion followed by paclitaxel 200 mg/m2 as a 3-hour infusion every 3 weeks
Number of subjects: 35
Study 9374092 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 plus paclitaxel 200 mg/m2
Number of subjects: 35
Study 9374092 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin plus paclitaxel
Number of subjects: 35
Study 1288930 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture on Zusanli points (ST36)
Number of subjects: 80
Study 1288930 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture anesthesia
Number of subjects: 80
Study 1288930 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 80
Study 3884881 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour creatinine clearance (24-hr CCr) in transplant patients
Number of subjects: 10
Study 3884881 — intervention group
Group type: COMPARATOR
Intervention: 24-hour creatinine clearance (24-hr CCr) in healthy women
Number of subjects: 10
Study 3884881 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean 24-hr CCr in late pregnancy in transplant patients
Number of subjects: 10
Study 3884881 — intervention group
Group type: COMPARATOR
Intervention: Mean 24-hr CCr in late pregnancy in healthy women
Number of subjects: 10
Study 3884881 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein excretion in transplant patients during pregnancy
Number of subjects: 10
Study 3884881 — intervention group
Group type: COMPARATOR
Intervention: Protein excretion in healthy women during pregnancy
Number of subjects: 10
Study 31330524 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal screening of children for FH
Number of subjects: 30
Study 29880276 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 8
Study 29880276 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 8
Study 29880276 — intervention group
Group type: COMPARATOR
Intervention: Carotid artery (c) vs Facial artery (f)
Number of subjects: 8
Study 29880276 — intervention group
Group type: COMPARATOR
Intervention: Carotid artery (c) vs Metatarsal artery (m)
Number of subjects: 8
Study 29880276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac output (Q˙t) and systemic vascular resistance (SVR)
Number of subjects: 8
Study 27932335 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg apixaban, administered twice daily for 3 years as adjunct therapy to stable oral PAH therapy
Number of subjects: 0
Study 27932335 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered twice daily for 3 years as adjunct therapy to stable oral PAH therapy
Number of subjects: 0
Study 27932335 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg apixaban
Number of subjects: 0
Study 27932335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27932335 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 0
Study 24431447 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold-contrast detection task
Number of subjects: 0
Study 24431447 — intervention group
Group type: COMPARATOR
Intervention: High-contrast speed discrimination task
Number of subjects: 0
Study 22612884 — intervention group
Group type: EXPERIMENTAL
Intervention: Music with headphones
Number of subjects: 119
Study 22612884 — intervention group
Group type: EXPERIMENTAL
Intervention: Headphones only
Number of subjects: 119
Study 22612884 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 119
Study 19309726 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (16 week RCT)
Number of subjects: 34
Study 19309726 — intervention group
Group type: COMPARATOR
Intervention: No depression (Control group)
Number of subjects: 34
Study 17868539 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose 4.5 g of azithromycin in 7 weeks
Number of subjects: 120
Study 17868539 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose 6.0 g of azithromycin in 10 weeks
Number of subjects: 120
Study 17868539 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose 7.5 g of azithromycin in 13 weeks
Number of subjects: 120
Study 15167314 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17beta‐estradiol + 0.125 mg trimegestone (n = 179)
Number of subjects: 360
Study 15167314 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 181)
Number of subjects: 360
Study 12851621 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril plus isosorbide-5-mononitrate (IS5MN)
Number of subjects: 177
Study 12851621 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril plus IS5MN
Number of subjects: 177
Study 12851621 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril plus isosorbide-5-mononitrate (IS5MN)
Number of subjects: 177
Study 12851621 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril plus IS5MN
Number of subjects: 177
Study 10579117 — intervention group
Group type: EXPERIMENTAL
Intervention: PiZ carriers
Number of subjects: 141
Study 10579117 — intervention group
Group type: EXPERIMENTAL
Intervention: BPI-ANCA
Number of subjects: 141
Study 10579117 — intervention group
Group type: EXPERIMENTAL
Intervention: PR3-ANCA
Number of subjects: 141
Study 8562413 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum eNCAM levels in patients with multiple myeloma
Number of subjects: 92
Study 8562413 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum eNCAM levels in patients with high tumour burdens
Number of subjects: 92
Study 8562413 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of serum eNCAM with beta 2-microglobulin
Number of subjects: 92
Study 8562413 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival of patients with low serum eNCAM
Number of subjects: 92
Study 8562413 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum eNCAM as a prognostic factor
Number of subjects: 92